Healthcare stocks were slightly higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each increasing about 0.1%.
The iShares Biotechnology ETF (IBB) was down 1%.
In corporate news, GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple myeloma from Chinese biotechnology company Chimagen Biosciences in a deal worth up to $750 million, as the UK drugmaker aims to strengthen its blood cancer treatment portfolio. GSK shares were up 0.1%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments